Peer-influenced content. Sources you trust. No registration required. This is HCN.

JAMA NetworkAssessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-Risk Breast Cancer

Publication: JAMA Oncology
An analysis of data from the I-SPY2 randomized clinical trial that included 938 women with breast cancer.
Results: In this randomized clinical trial, the prognostic significance of RCB was consistent regardless of cancer subtype and treatment.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form